Citations

Clear

368 citation(s) found for "Wolf, DM".

Voriconazole exposure and the risk of cutaneous squamous cell carcinoma in allogeneic hematopoietic stem cell transplant patients
Wojenski, Daniel, Bartoo, Gabriel , Merten, Julianna A., Dierkhising, Ross , Barajas, M, Wilson, John , Plevak, Matt, Litzow, Mark R. , Patnaik, Mrinal M. , Hashmi, Shahrukh K. , el‐Azhary, Rokea A. , Hogan, William J. , Wolf, Robert Christian

Mayo Clinic

Transplant Infectious Disease | February 6, 2015 | Volume: 17 | Issue: 2 | Pages: 250-258

10.1111/tid.12367 | PMID 25661996 Get It

AbstractBackgroundVoriconazole is a commonly used antifungal medication in allogeneic hematopoietic stem cell transplantation (allo‐HSCT) patients. In solid organ transplantation, voriconazole use has been associated with the development of cutaneous squamous cell carcinoma (SCC). We sought to determine if voriconazole use was associated with SCC in patients undergoing allo‐HSCT.MethodsWe retrospectively reviewed consecutive adult patients who underwent allo‐HSCT at Mayo Clinic from January 2007 through July 2012. Multivariable Cox models were created to assess the relationship of SCC with two time‐dependent voriconazole exposure variables: (i) history of voriconazole exposure (yes/no), and (ii) cumulative days of voriconazole use.ResultsIn our cohort of 381 allo‐HSCT patients, SCC developed in 26 of 312 patients exposed to voriconazole (25 post‐voriconazole) and in 1 of 69 patients who received alternative antifungal agent(s). Cumulative incidence of SCC was estimated to be 19% at 5 years post allo‐transplant. Cumulative days of voriconazole use was found to be a risk factor for SCC, and this relationship persisted in a multivariable model using previously identified risk factors as covariates (hazard ratio 1.859 for each 180 days of use, P < 0.001).ConclusionThis is the first study, to our knowledge, to identify cumulative days of voriconazole use as a risk factor for SCC development following allo‐HSCT, and may help guide appropriate antifungal use in this patient population.
Training labels for hippocampal segmentation based on the EADC‐ADNI harmonized hippocampal protocol
Boccardi, Marina , Bocchetta, Martina , Morency, Félix C., Collins, D. Louis , Nishikawa, Masami, Ganzola, Rossana , Grothe, Michel J. , Redolfi, Alberto , Pievani, Michela , Antelmi, Luigi , Fellgiebel, Andreas , Duchesne, Simon , Jack, Clifford R. , Frisoni, Giovanni B. , Initiative, EADC‐ADNI Working Group on The Harmonized Protocol for Manual Hippocampal Segmentation and for the Alzheimer's Disease Neuroimaging, Boccardi, Marina , Frisoni, Giovanni B. , Wolf, Dominik Georg Friedrich , Matsuda, Hiroshi , Teipel, Stefan Johannes , Initiative, EADC‐ADNI Working Group on The Harmonized Protocol for Manual Hippocampal Segmentation and for the Alzheimer's Disease Neuroimaging, Jack, Clifford R , Grothe, Michel J , Bocchetta, Martina

Mayo Clinic

Alzheimer's & Dementia | January 20, 2015 | Volume: 11 | Issue: 2 | Pages: 175-183

10.1016/j.jalz.2014.12.002 | PMID 25616957 Get It

AbstractBackgroundThe European Alzheimer's Disease Consortium and Alzheimer's Disease Neuroimaging Initiative (ADNI) Harmonized Protocol (HarP) is a Delphi definition of manual hippocampal segmentation from magnetic resonance imaging (MRI) that can be used as the standard of truth to train new tracers, and to validate automated segmentation algorithms. Training requires large and representative data sets of segmented hippocampi. This work aims to produce a set of HarP labels for the proper training and certification of tracers and algorithms.MethodsSixty‐eight 1.5 T and 67 3 T volumetric structural ADNI scans from different subjects, balanced by age, medial temporal atrophy, and scanner manufacturer, were segmented by five qualified HarP tracers whose absolute interrater intraclass correlation coefficients were 0.953 and 0.975 (left and right). Labels were validated as HarP compliant through centralized quality check and correction.ResultsHippocampal volumes (mm3) were as follows: controls: left = 3060 (standard deviation [SD], 502), right = 3120 (SD, 897); mild cognitive impairment (MCI): left = 2596 (SD, 447), right = 2686 (SD, 473); and Alzheimer’s disease (AD): left = 2301 (SD, 492), right = 2445 (SD, 525). Volumes significantly correlated with atrophy severity at Scheltens' scale (Spearman's ρ = <−0.468, P = <.0005).Cerebrospinal fluid spaces (mm3) were as follows: controls: left = 23 (32), right = 25 (25); MCI: left = 15 (13), right = 22 (16); and AD: left = 11 (13), right = 20 (25). Five subjects (3.7%) presented with unusual anatomy.ConclusionsThis work provides reference hippocampal labels for the training and certification of automated segmentation algorithms. The publicly released labels will allow the widespread implementation of the standard segmentation protocol.
Smile without euphoria induced by deep brain stimulation: a case report
Foote, Kelly D. , Archer, Derek B. , Coombes, Stephen A. , Vaillancourt, David E. , Hassan, Anhar , Haq, Ihtsham , Wolf, Janine, Okun, Michael S. , Morishita, Takashi , Okun, Michael S , Haq, Ihtsham , Archer, Derek

Mayo Clinic

Neurocase | October 31, 2014 | Volume: 21 | Issue: 6 | Pages: 674-678

10.1080/13554794.2014.973883 | PMID 25360766 Get It

Strategy for prevention of cancers of the esophagus
Akiyama, Junichi, Alexandre, Leo , Baruah, Anushka , Buttar, Navtej , Chandra, Raghav , Clark, Allan , Hart, Andrew , Hawk, Ernest T. , Kandioler, Daniela , Kappel, Sonja, Krishnadath, Sheila, Sharma, Anamay N. , Singh, Ishtpreet, Straub, Daniëlle, Triadafilopoulos, George , Wolf, Brigitte , Umar, Asad , Triadafilopoulos, George

Mayo Clinic

Annals of the New York Academy of Sciences | September 29, 2014 | Volume: 1325 | Issue: 1 | Pages: 108-126

10.1111/nyas.12529 | PMID 25266020 Get It

The following, from the 12th OESO World Conference: Cancers of the Esophagus, includes commentaries on the animal reflux–inflammation models for Barrett's esophagus and esophageal adenocarcinoma; genomic/epigenomic analyses; eflornithine‐based combinations; the molecular derangements that promote neoplastic transformation; the role of COX‐2 inhibitors, proton pump inhibitors, and phase II trials in Barrett's adenocarcinoma; statins in chemoprevention and treatment of esophageal cancer; and biomarkers as potential targets in Barrett's adenocarcinoma.
The EADC‐ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity
Frisoni, Giovanni B. , Jack, Clifford R. , Bocchetta, Martina , Frederiksen, Kristian Steen , Liu, Yawu , Preboske, Gregory M., Swihart, Tim, Blair, Melanie , Cavedo, Enrica , Grothe, Michel J. , Lanfredi, Mariangela , Martinez, Oliver, Nishikawa, Masami, Portegies, Marileen, Stoub, Travis , Ward, Chadwich, Apostolova, Liana G. , Ganzola, Rossana , Barkhof, Frederik , Bartzokis, George, DeCarli, Charles , Csernansky, John G., deToledo‐Morrell, Leyla, Geerlings, Mirjam I. , Lehéricy, Stéphane , O’Brien, John T. , Silbert, Lisa C. , Scheltens, Philip , Waldemar, Gunhild, Fellgiebel, Andreas , Barnes, Josephine , Gerritsen, Lotte , Henneman, Wouter J.P., Malykhin, Nikolai , Pruessner, Jens C. , Watson, Craig, Leon, Mony J. de , Pantel, Johannes, Ferrari, Clarissa , Bosco, Paolo , Pasqualetti, Patrizio , Duchesne, Simon , Duvernoy, Henri M., Boccardi, Marina , Initiative, EADC‐ADNI Working Group on The Harmonized Protocol for Manual Hippocampal Volumetry and for the Alzheimer's Disease Neuroimaging, Albert, Marilyn S. , Bennet, David, Camicioli, Richard , Collins, D. Louis , Dubois, Bruno , Hampel, Harald , denHeijer, Tom, Hock, Christofer, Jagust, William J. , Launer, Leonore J., Maller, Jerome J. , Mueller, S. G., Sachdev, Perminder S. , Simmons, Andy, Visser, Peter‐Jelle, Wahlund, Lars‐Olof , Weiner, Michael W. , Winblad, Bengt , Boccardi, Marina , Frisoni, Giovanni B. , DeCarli, Charles , Preboske, Gregory, Bauer, Corinna M. , Wolf, Dominik Georg Friedrich , Kaye, Jeffrey , Killiany, Ronald , Matsuda, Hiroshi , O'Brien, John Tiernan , Soininen, Hilkka S. , Teipel, Stefan Johannes , Waldemar, Gunhild , Firbank, Michael John , Wang, Lei , Wolf, Henrike , Initiative, EADC‐ADNI Working Group on The Harmonized Protocol for Manual Hippocampal Volumetry and for the Alzheimer's Disease Neuroimaging, Thompson, Paul M. , Jack, Clifford R , Sachdev, Perminder S , Barkhof, Frederik , Scheltens, Philip , Wahlund, Lars-Olof , Grothe, Michel J , Bocchetta, Martina , Stoub, Travis

Mayo Clinic

Alzheimer's & Dementia | September 27, 2014 | Volume: 11 | Issue: 2 | Pages: 111-125

10.1016/j.jalz.2014.05.1756 | PMID 25267715 Get It

Abstract Background An international Delphi panel has defined a harmonized protocol (HarP) for the manual segmentation of the hippocampus on MR. The aim of this study is to study the concurrent validity of the HarP toward local protocols, and its major sources of variance. Methods Fourteen tracers segmented 10 Alzheimer's Disease Neuroimaging Initiative (ADNI) cases scanned at 1.5 T and 3T following local protocols, qualified for segmentation based on the HarP through a standard web‐platform and resegmented following the HarP. The five most accurate tracers followed the HarP to segment 15 ADNI cases acquired at three time points on both 1.5 T and 3T. Results The agreement among tracers was relatively low with the local protocols (absolute left/right ICC 0.44/0.43) and much higher with the HarP (absolute left/right ICC 0.88/0.89). On the larger set of 15 cases, the HarP agreement within (left/right ICC range: 0.94/0.95 to 0.99/0.99) and among tracers (left/right ICC range: 0.89/0.90) was very high. The volume variance due to different tracers was 0.9% of the total, comparing favorably to variance due to scanner manufacturer (1.2), atrophy rates (3.5), hemispheric asymmetry (3.7), field strength (4.4), and significantly smaller than the variance due to atrophy (33.5%, P < .001), and physiological variability (49.2%, P < .001). Conclusions The HarP has high measurement stability compared with local segmentation protocols, and good reproducibility within and among human tracers. Hippocampi segmented with the HarP can be used as a reference for the qualification of human tracers and automated segmentation algorithms.
Harmonized benchmark labels of the hippocampus on magnetic resonance: The EADC‐ADNI project
Bocchetta, Martina , Boccardi, Marina , Ganzola, Rossana , Apostolova, Liana G. , Preboske, Gregory M., Ferrari, Clarissa , Pasqualetti, Patrizio , Robitaille, Nicolas , Duchesne, Simon , Jack, Clifford R. , Frisoni, Giovanni B. , Initiative, EADC‐ADNI Working Group on The Harmonized Protocol for Manual Hippocampal Segmentation and for the Alzheimer's Disease Neuroimaging, Bartzokis, George, deToledo‐Morrell, Leyla, Fellgiebel, Andreas , Gerritsen, Lotte , Henneman, Wouter J.P., Malykhin, Nikolai , Pruessner, Jens C. , Watson, Craig, Boccardi, Marina , Frisoni, Giovanni B. , Preboske, Gregory, Wolf, Dominik Georg Friedrich , Initiative, EADC‐ADNI Working Group on The Harmonized Protocol for Manual Hippocampal Segmentation and for the Alzheimer's Disease Neuroimaging, DeCarli, Charles , Firbank, Michael John , Killiany, Ronald , Soininen, Hilkka S. , Wang, Lei , Wolf, Henrike , Jack, Clifford R , Bocchetta, Martina

Mayo Clinic

Alzheimer's & Dementia | September 13, 2014 | Volume: 11 | Issue: 2 | Pages: 151

10.1016/j.jalz.2013.12.019 | PMID 25223727 Get It

AbstractBackgroundA globally harmonized protocol (HarP) for manual hippocampal segmentation based on magnetic resonance has been recently developed by a task force from European Alzheimer's Disease Consortium (EADC) and Alzheimer's Disease Neuroimaging Initiative (ADNI). Our aim was to produce benchmark labels based on the HarP for manual segmentation.MethodsFive experts of manual hippocampal segmentation underwent specific training on the HarP and segmented 40 right and left hippocampi from 10 ADNI subjects on both 1.5 T and 3 T scans. An independent expert visually checked segmentations for compliance with the HarP. Descriptive measures of agreement between tracers were intraclass correlation coefficients (ICCs) of crude volumes and similarity coefficients of three‐dimensional volumes.ResultsTwo hundred labels have been provided for the 20 magnetic resonance images. Intra‐ and interrater ICCs were >0.94, and mean similarity coefficients were 1.5 T, 0.73 (95% confidence interval [CI], 0.71–0.75); 3 T, 0.75 (95% CI, 0.74–0.76).ConclusionCertified benchmark labels have been produced based on the HarP to be used for tracers' training and qualification.
Plasma amyloid‐β and risk of Alzheimer's disease in the Framingham Heart Study
Beiser, Alexa , Younkin, Linda H., Preis, Sarah R. , Hansson, Oskar , Lambert, Jean‐Charles , Wolf, Philip A. , Younkin, Steven G., Seshadri, Sudha , Younkin, Linda, Younkin, Steven, Chouraki, Vincent Antoine , Weinstein, Galit , Skoog, Ingmar , Au, Rhoda , Launer, Lenore J. , Seshadri, Sudha , Hansson, Oskar

Mayo Clinic

Alzheimer's & Dementia | September 10, 2014 | Volume: 11 | Issue: 3 | Pages: 249

10.1016/j.jalz.2014.07.001 | PMID 25217292 Get It

AbstractBackgroundPlasma amyloid‐β (Aβ) peptide levels have been examined as a low‐cost accessible marker for risk of incident Alzheimer's disease (AD) and dementia, but results have varied between studies. We reassessed these associations in one of the largest, prospective, community‐based studies to date.MethodsA total of 2189 dementia‐free, Framingham Study participants aged >60 years (mean age, 72 ± 8 years; 56% women) had plasma Aβ1‐42 and Aβ1‐40 measured and were followed prospectively (mean, 7.6 ± 3.0 years) for dementia/AD.ResultsIncreased plasma Aβ1‐42 levels were associated with lower risk of dementia (Aβ1‐42: hazard ratio [HR] = 0.80 [0.71‒0.90], P < .001; Aβ1‐42‐to‐Aβ1‐40 ratio: HR = 0.86 [0.76‒0.98], P = .027) and AD (Aβ1‐42: HR = 0.79 [0.69‒0.90], P < .001; Aβ1‐42‐to‐Aβ1‐40 ratio: HR = 0.83 [0.72‒0.96], P = .012).ConclusionOur results suggest that lower plasma Aβ levels are associated with risk of incident AD and dementia. They encourage further evaluation of plasma Aβ levels as a biomarker for risk of developing clinical AD and dementia.
Delphi definition of the EADC‐ADNI Harmonized Protocol for hippocampal segmentation on magnetic resonance
Boccardi, Marina , Bocchetta, Martina , Apostolova, Liana G. , Barnes, Josephine , Bartzokis, George, Corbetta, Gabriele , DeCarli, Charles , deToledo‐Morrell, Leyla, Ganzola, Rossana , Gerritsen, Lotte , Henneman, Wouter J.P., Malykhin, Nikolai , Pasqualetti, Patrizio , Pruessner, Jens C. , Redolfi, Alberto , Robitaille, Nicolas , Tolomeo, Daniele , Watson, Craig, Duvernoy, Henri M., Duchesne, Simon , Jack, Clifford R. , Frisoni, Giovanni B. , Segmentation, EADC‐ADNI Working Group on the Harmonized Protocol for Manual Hippocampal, Boccardi, Marina , Frisoni, Giovanni B. , DeCarli, Charles , Firbank, Michael John , Killiany, Ronald , Soininen, Hilkka S. , Wang, Lei , Wolf, Henrike , Segmentation, EADC‐ADNI Working Group on the Harmonized Protocol for Manual Hippocampal, Jack, Clifford R , Bocchetta, Martina

Mayo Clinic

Alzheimer's & Dementia | August 15, 2014 | Volume: 11 | Issue: 2 | Pages: 126-138

10.1016/j.jalz.2014.02.009 | PMID 25130658 Get It

Abstract Background This study aimed to have international experts converge on a harmonized definition of whole hippocampus boundaries and segmentation procedures, to define standard operating procedures for magnetic resonance (MR)‐based manual hippocampal segmentation. Methods The panel received a questionnaire regarding whole hippocampus boundaries and segmentation procedures. Quantitative information was supplied to allow evidence‐based answers. A recursive and anonymous Delphi procedure was used to achieve convergence. Significance of agreement among panelists was assessed by exact probability on Fisher's and binomial tests. Results Agreement was significant on the inclusion of alveus/fimbria ( P = .021), whole hippocampal tail ( P = .013), medial border of the body according to visible morphology ( P = .0006), and on this combined set of features ( P = .001). This definition captures 100% of hippocampal tissue, 100% of Alzheimer’s disease‐related atrophy, and demonstrated good reliability on preliminary intrarater (0.98) and inter‐rater (0.94) estimates. Discussion Consensus was achieved among international experts with respect to hippocampal segmentation using MR resulting in a harmonized segmentation protocol.
Ex‐vivo testing and preclinical heterotopic thoracic cardiac xenotransplantation of multi‐transgenic organs
Mayr, Tanja, Guethoff, Sonja , Buchholz, Stefan, Werner, Fabian, Baehr, Andrea , Klymiuk, Nikolai , Wuensch, A., Wolf, Eckhart, Belka, Claus , Ayares, David , Niemann, Heiner , Bongoni, Anjan K. , McGregor, Christopher G.A. , Reichart, Bruno , Brenner, Paolo , Abicht, Jan‐Michael , Petersen, Björn , Rieben, Robert

Mayo Clinic

Xenotransplantation | April 19, 2014 | Volume: 21 | Issue: 2 | Pages: 190-191

10.1111/xen.12083_14 Get It

The heterotopic thoracic pig‐to‐baboon heart transplantation has been established by our group as a safe preclinical model. Since the recipient's own heart remains in place, it is possible to evaluate immunological reactions of various types and the symptoms of the thrombotic microangiopathy under working heart conditions. However, these experiments are complex and costly. In order to limit the number of transplants, we tested our multi‐transgenic porcine donor hearts in an ex‐vivo perfusion model first.Ex‐vivo model: Both beating ventricles were perfused with heparinized freshly drawn human whole blood using a centrifugal pump and a membrane oxygenator. During 3 h of observation, cardiac function parameters were obtained continuously; specimens from the perfusate, coronary sinus blood, and myocardial biopsies were assessed. Various genetically modified porcine donor hearts were tested; we are currently evaluating the impact of human thrombomodulin on the porcine microcirculation; the efficacy of complement regulation is another work package.Pig‐to‐baboon heterotopic cardiac xenotransplantation: In our latest group, seven baboons received five double (Gal‐KO/hCD46), and two triple (Gal‐KO/hCD46/hTM resp./HLA‐E) transgenic pig hearts. Our immunosuppressive regimen included preoperative anti‐CD20‐antibody, bortezomib, dexamethasone and cyclophosphamide; postoperatively, ATG, tacrolimus, MMF, anti‐CD20‐antibody, bortezomib and dexamethasone were administered. Total lymph node irradiation (6 Gy) was applied on postoperative day five.The triple transgenic hearts survived 35 and 37 days respectively. Both hearts maintained function throughout the experiment. Both recipients succumbed to fungal infections. Humoral rejection was seen only once. The next barrier appears to be the complex event of thrombotic microangiopathy that needs to be addressed with the additional expression of human thrombomodulin strategies.